☆ 4.2 Article

Infectious adverse events in patients with atopic dermatitis treated with baricitinib

IMMUNOTHERAPY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Dermatology

Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials

Thomas Bieber et al.

Summary: Baricitinib demonstrated a consistent safety profile in the long-term treatment of atopic dermatitis patients, with no new safety signals identified. The incidence rates of major adverse cardiovascular events, deep vein thromboses/pulmonary emboli, malignancies, and serious infections were within the ranges observed in the background population of patients with AD.

JOURNAL OF DERMATOLOGICAL TREATMENT (2023)

添加到收藏夹

Article Dermatology

Long-term efficacy (up to 68 weeks) of Baricitinib in combination with topical corticosteroids in adult patients with moderate-to-severe atopic dermatitis: Analysis of treatment responders, partial responders and nonresponders originating from study BREEZE-AD7

Jonathan I. Silverberg et al.

Summary: Baricitinib combined with topical corticosteroids (TCS) has shown sustained efficacy in treating adults with moderate-to-severe atopic dermatitis (AD) over a 68-week period.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

添加到收藏夹

Review Dermatology

Expert consensus on the systemic treatment of atopic dermatitis in special populations

D. N. Adam et al.

Summary: With the increasing number of treatment options for moderate-to-severe atopic dermatitis, an expert panel reviewed relevant data and formulated consensus statements on the choice of systemic agents for specific patient populations. They examined six clinical scenarios, including comorbidities and pregnancy, and evaluated three major categories of systemic agents. The resulting 25 consensus statements and supporting data provide practical guidance for selecting systemic therapy for atopic dermatitis.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

添加到收藏夹

Article Medicine, Research & Experimental

Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications

Peter C. Taylor et al.

Summary: This study evaluated the adverse events of special interest (AESI) in patients receiving baricitinib for rheumatoid arthritis, atopic dermatitis, and alopecia areata. It found that the incidence of AESI was low in both low-risk and at-risk populations, particularly in dermatologic indications.

ADVANCES IN THERAPY (2023)

添加到收藏夹

Article Dermatology

Efficacy and safety of baricitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan

Teppei Hagino et al.

Summary: The efficacy and safety of baricitinib for atopic dermatitis were evaluated. The results showed that oral baricitinib, combined with topical corticosteroids, improved clinical indexes and demonstrated good performance in real-world practice.

JOURNAL OF DERMATOLOGY (2023)

添加到收藏夹

Editorial Material Dermatology

Treatment of Atopic Dermatitis with Baricitinib: First Real-life Experience

Danielle Rogner et al.

ACTA DERMATO-VENEREOLOGICA (2022)

添加到收藏夹

Article Dermatology

Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials

K. Reich et al.

Summary: The study evaluated the impact of baricitinib on patient-reported outcomes in adult patients with moderate-to-severe AD, showing significant reduction in itch severity and improvements in symptoms, particularly with a clear association with improvements in disease severity and quality of life.

JOURNAL OF DERMATOLOGICAL TREATMENT (2022)

添加到收藏夹

Review Immunology

Affecting the effectors: JAK inhibitors modulation of immune cell numbers and functions in patients with rheumatoid arthritis

Cristina Garufi et al.

Summary: This review summarizes the effects of Jakinibs on immune populations. Although Jakinibs have an impact on the numbers and function of immune cells, they do not seem to pose a major safety issue.

EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2022)

添加到收藏夹

Review Immunology

The infection risks of JAK inhibition

Maryam A. Adas et al.

Summary: Licensed JAK inhibitors have shown increased risk of infection compared to placebo, affecting respiratory and urinary tracts, nasopharynx, and skin. This risk is dose-dependent and similar to that seen with biologic therapies. Other risk factors for infection, such as age and steroid co-prescription, further compound the risk.

EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2022)

添加到收藏夹

Review Rheumatology

Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach

Yoshiya Tanaka et al.

Summary: This Review discusses the therapeutic use of Janus kinase inhibitors in autoimmune rheumatic diseases, highlighting their disease-specific mechanisms of action. JAK inhibitors suppress intracellular signaling mediated by multiple cytokines, offering potential treatment options for a range of immune and inflammatory disorders.

NATURE REVIEWS RHEUMATOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis

Steven R. Ytterberg et al.

Summary: In this trial comparing the use of tofacitinib with a TNF inhibitor in a cardiovascular risk-enriched population, the risks of major adverse cardiovascular events (MACE) and cancers were found to be higher with tofacitinib, and it did not meet noninferiority criteria. Several adverse events were more common with tofacitinib.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Review Dermatology

Baricitinib: A Review in Moderate to Severe Atopic Dermatitis

Sheridan M. Hoy

Summary: Baricitinib is an oral alternative for the treatment of moderate to severe atopic dermatitis in adults. It provides significant and rapid improvements in disease severity and quality of life, making it a potential option for patients who are candidates for systemic therapy.

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2022)

添加到收藏夹

Editorial Material Dermatology

Herpesvirus, serious and opportunistic infections associated with atopic dermatitis

Natalija Novak et al.

BRITISH JOURNAL OF DERMATOLOGY (2022)

添加到收藏夹

Article Dermatology

Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4)

Thomas Bieber et al.

Summary: This study demonstrated that baricitinib combined with background topical corticosteroids can provide sustained improvements in the signs and symptoms of moderate-to-severe atopic dermatitis for up to 1 year, particularly in patients who have contraindications or inadequate response to ciclosporin A. The most common treatment-emergent adverse events with baricitinib 4 mg were nasopharyngitis, herpes simplex, influenza, and headache, and the safety profile was consistent with previous studies in patients with moderate-to-severe atopic dermatitis.

BRITISH JOURNAL OF DERMATOLOGY (2022)

添加到收藏夹

Editorial Material Dermatology

Real-world effectiveness and safety of baricitinib in Japanese patients with atopic dermatitis: A single-center retrospective study

Akihiko Uchiyama et al.

JOURNAL OF DERMATOLOGY (2022)

添加到收藏夹

Article Dermatology

An integrated analysis of herpes virus infections from eight randomized clinical studies of baricitinib in adults with moderate-to-severe atopic dermatitis

T. Werfel et al.

Summary: This study examined the occurrence of herpes simplex infections in adult patients with AD receiving baricitinib treatment. The study found that herpes simplex was common, eczema herpeticum occurred less frequently, and herpes zoster events were rare and not dose-dependent. Most herpes simplex events were mild or moderate, and rarely led to permanent discontinuation.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2022)

添加到收藏夹

Review Immunology

Application of Baricitinib in Dermatology

Jingya Zhang et al.

Summary: Baricitinib, a JAK1/2 inhibitor, has shown promising results in the treatment of various skin diseases, including rheumatoid arthritis and alopecia areata.

JOURNAL OF INFLAMMATION RESEARCH (2022)

添加到收藏夹

Review Medicine, Research & Experimental

A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19

Thomas Bieber et al.

Summary: Baricitinib is an oral, selective inhibitor of Janus kinase (JAK)1/JAK2 that transiently and reversibly inhibits proinflammatory cytokines. It has been approved for the treatment of rheumatological, dermatological disorders, and COVID-19. The safety profile of baricitinib varies across these diseases, with rates of infection and adverse cardiovascular events generally reflecting the inherent risk in the respective disease populations. Adverse events of special interest were more common in patients with risk factors specific to each event. Short-term use of baricitinib in hospitalized patients with COVID-19 did not raise safety concerns.

ADVANCES IN THERAPY (2022)

添加到收藏夹

Article Dermatology

European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy

A. Wollenberg et al.

Summary: The evidence- and consensus-based guideline on atopic eczema, developed according to the EuroGuiDerm Guideline and Consensus Statement Development Manual, involves the participation of 29 experts from 12 European countries. The first part of the guideline provides general information, guidance, and detailed information on systemic treatment options, including conventional immunosuppressive drugs, biologics, and janus kinase inhibitors. The second part will cover other aspects of treatment.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2022)

添加到收藏夹

Article Dermatology

Pooled Safety Analysis of Baricitinib in Adult Participants with Atopic Dermatitis in the Japanese Subpopulation from Six Randomized Clinical Trials

Norito Katoh et al.

Summary: This study provides pooled safety data for baricitinib in the Japanese subpopulation with moderate-to-severe atopic dermatitis. The results show that baricitinib has a similar safety profile in the Japanese population compared to the global study population, with no serious adverse events or deaths reported after up to 2 years of exposure.

DERMATOLOGY AND THERAPY (2022)

添加到收藏夹

Article Dermatology

Daily Practice Experience of Baricitinib Treatment for Patients with Difficult-to-Treat Atopic Dermatitis: Results from the BioDay Registry

Celeste M. Boesjes et al.

ACTA DERMATO-VENEREOLOGICA (2022)

添加到收藏夹

Review Allergy

New treatments in atopic dermatitis

Neha Puar et al.

Summary: The review discusses the efficacy and safety of novel and emerging topical and systemic therapeutic agents for atopic dermatitis, highlighting the new drugs currently in clinical trials and future directions. It emphasizes the need to develop new targeted therapies for effective management of atopic dermatitis and outlines future research focus areas in developing predictive models for personalized management options.

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2021)

添加到收藏夹

Article Dermatology

Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials

T. Bieber et al.

Summary: This study reports pooled safety data for baricitinib in patients with moderate-to-severe AD, confirming the established safety profile of baricitinib in this population.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)

添加到收藏夹

Article Dermatology

Baricitinib in patients with moderate-tosevere atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)

Eric L. Simpson et al.

Summary: The study evaluated the efficacy and safety of baricitinib monotherapy in patients with moderate-to-severe AD who responded inadequately or were intolerant to topical therapy. Results showed a higher proportion of patients achieving efficacy endpoints in the baricitinib groups at week 16.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)

添加到收藏夹

Article Dermatology

Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials

Brett King et al.

Summary: This study evaluated the safety of baricitinib 2 mg in treating moderate-to-severe AD, and found that treatment-emergent adverse events were higher with the drug compared to placebo, but serious adverse events were low and similar between the two groups. The integrated analysis confirmed the established safety profile of baricitinib 2 mg in patients with AD, but longer exposure to treatment is needed to assess the risks of malignancies and major adverse cardiovascular events.

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

Baricitinib: From Rheumatoid Arthritis to COVID-19

Sara Assadiasl et al.

Summary: Baricitinib is a JAK1/2 inhibitor approved for treating moderate to severe rheumatoid arthritis and has shown efficacy in controlling exaggerated inflammatory responses in various diseases. Clinical trials and case reports demonstrate improvements in patients treated with baricitinib, but adverse effects have been observed, urging further investigation before widespread use.

JOURNAL OF CLINICAL PHARMACOLOGY (2021)

添加到收藏夹

Article Dermatology

Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE-AD7 Phase 3 randomized trial

A. Wollenberg et al.

Summary: Baricitinib plus TCS showed significant improvements in HRQoL, work productivity, and life functioning in patients with moderate-to-severe AD, indicating its potential as an effective treatment option.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)

添加到收藏夹

Review Medicine, General & Internal

Atopic Dermatitis

Sonja Staender

Summary: Atopic dermatitis is a chronic condition that typically begins in childhood and can persist into adulthood, with treatment options including both topical and systemic approaches targeting the underlying immune condition.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Review Allergy

JAK inhibitors in the treatment of atopic dermatitis

Raj Chovatiya et al.

Summary: Atopic dermatitis (AD) is a chronic inflammatory skin disorder with limited treatment options. Recent studies have shown that both topical and systemic Janus kinase (JAK) inhibitors hold promise in treating AD, with further research needed to fully understand their efficacy and safety.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2021)

添加到收藏夹

Article Dermatology

Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phaseIIItrials

E. L. Simpson et al.

BRITISH JOURNAL OF DERMATOLOGY (2020)

添加到收藏夹

Article Dermatology

Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis A Randomized Clinical Trial

Kristian Reich et al.

JAMA DERMATOLOGY (2020)

添加到收藏夹

Review Dermatology

Counting the Burden: Atopic Dermatitis and Health-related Quality of Life

Faraz Ali et al.

ACTA DERMATO-VENEREOLOGICA (2020)

添加到收藏夹

Article Dermatology

Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study

Emma Guttman-Yassky et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)

添加到收藏夹

Review Dermatology

More than skin deep: the systemic nature of atopic dermatitis

Clara Oliveira et al.

EUROPEAN JOURNAL OF DERMATOLOGY (2019)

添加到收藏夹

Article Dermatology

Skin diseases associated with atopic dermatitis

Justine Fenner et al.

CLINICS IN DERMATOLOGY (2018)

添加到收藏夹

Article Medicine, Research & Experimental

JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies

Gina A. Montealegre Sanchez et al.

JOURNAL OF CLINICAL INVESTIGATION (2018)

添加到收藏夹

Review Dermatology

Major Comorbidities of Atopic Dermatitis: Beyond Allergic Disorders

Amy Paller et al.

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2018)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.